Brian L. Kotzin — Head of Clinical Development for Nektar's Immunology Program at Nektar Therapeutics

Dr. Brian L. Kotzin, M.D. has been the Head of Clinical Development for Nektar's Immunology Program at Nektar Therapeutics since May 03, 2017. Dr. Kotzin leads clinical development for NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders. Dr. Kotzin is a highly respected clinical researcher with an outstanding reputation and over 30 years of expertise in inflammation and immunology. Dr. Kotzin served as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area of Amgen Inc. from July 12, 2004 to 2015 and served as Head of Medical Sciences. Dr. Kotzin directs the global development efforts for all new Amgen product candidates in the inflammation area. During his time at Amgen, he also served as Vice President of Medical Sciences. Dr. Kotzin joined Amgen from the University of Colorado Health Sciences Center in Denver, where he served as Head of Clinical Immunology in the Department of Medicine. He held the position of Professor in the Departments of Medicine, Pediatrics and Immunology at the National Jewish Medical and Research Center in Denver. Dr. Kotzin served at the Veterans Administration Medical Center in Denver as chief of the Rheumatology Section. Dr. Kotzin serves as a Member of Scientific Advisory Board at Biocon Limited. He has been a Director at Rigel Pharmaceuticals, Inc. since August 2017. He serves as a Member of the Board of Directors at Federation of Clinical Immunology Societies (FOCIS). Dr. Kotzin served as Chairmanship of the National Institutes of Health Autoimmunity Centers of Excellence. Dr. Kotzin served as an Industry Representative, Arthritis Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration (FDA). Dr. Kotzin was appointed to the Advisory Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health. He has published extensively and served on the editorial boards of Arthritis and Rheumatism, The Journal of Immunology and the Journal of Clinical Investigation. He is an Associate Editor at Clinical Investigation. He is board certified in rheumatology and internal medicine. A board-certified rheumatologist and internist, Dr. Kotzin is Principal Fellow, Clinical Development at Nektar Therapeutics. He is an elected member of the American Association of Clinical Investigation and the Association of American Physicians. Dr. Kotzin has won numerous honors, including elected Master of the American College of Rheumatology, the Kirkland Scholar Award for Lupus Research, the Henry Claman Chair in Clinical Immunology, the Gretchen Kramer Award for Outstanding Contributions to Medicine and Chairmanship of the National Institutes of Health Autoimmunity Centers of Excellence. He holds Post-Doctoral Fellowship in Immunology & Rheumatology from Stanford University. He received his Medical Degree from Stanford and undergraduate degree in Mathematics from the University of Southern California.